Structural Basis for Antibody Cross-neutralization of Respiratory Syncytial Virus and Human Metapneumovirus

Overview

Journal Nat Microbiol

Specialties Microbiology
Parasitology

Date 2017 Jan 31

PMID 28134915

Citations 50

Authors

Xiaolin Wen

Jarrod J Mousa

John T Bates

Robert A Lamb

James E Crowe Jr

Theodore S Jardetzky

Affiliations

Soon will be listed here.

Abstract

Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are two closely related viruses that cause bronchiolitis and pneumonia in infants and the elderly, with a significant health burden. There are no licensed vaccines or small-molecule antiviral treatments specific to these two viruses at present. A humanized murine monoclonal antibody (palivizumab) is approved to treat high-risk infants for RSV infection, but other treatments, as well as vaccines, for both viruses are still in development. Recent epidemiological modelling suggests that cross-immunity between RSV, HMPV and human parainfluenzaviruses may contribute to their periodic outbreaks, suggesting that a deeper understanding of host immunity to these viruses may lead to enhanced strategies for their control. Cross-reactive neutralizing antibodies to the RSV and HMPV fusion (F) proteins have been identified. Here, we examine the structural basis for cross-reactive antibody binding to RSV and HMPV F protein by two related, independently isolated antibodies, MPE8 and 25P13. We solved the structure of the MPE8 antibody bound to RSV F protein and identified the 25P13 antibody from an independent blood donor. Our results indicate that both antibodies use germline residues to interact with a conserved surface on F protein that could guide the emergence of cross-reactivity. The induction of similar cross-reactive neutralizing antibodies using structural vaccinology approaches could enhance intrinsic cross-immunity to these paramyxoviruses and approaches to controlling recurring outbreaks.

Citing Articles

DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection.

Yang Y, Wang R, Guo F, Zhao T, Lei Y, Yang Q NPJ Vaccines. 2024; 9(1):258.

PMID: 39741146 PMC: 11688450. DOI: 10.1038/s41541-024-01059-9.

Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.

Tartof S, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B JAMA Netw Open. 2024; 7(12):e2450832.

PMID: 39671195 PMC: 11645642. DOI: 10.1001/jamanetworkopen.2024.50832.

A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein.

Sun Y, Liu L, Qiang H, Sun H, Jiang Y, Ren L Nat Commun. 2024; 15(1):10085.

PMID: 39572535 PMC: 11582626. DOI: 10.1038/s41467-024-54384-x.

Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus.

Lee Y, Han J, Zhang Y, Ward G, Gomes K, Auclair S Nat Commun. 2024; 15(1):9939.

PMID: 39550381 PMC: 11569192. DOI: 10.1038/s41467-024-54287-x.

Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies.

Scharffenberger S, Wan Y, Homad L, Kher G, Haynes A, Poudel B Cell Rep. 2024; 43(10):114811.

PMID: 39383036 PMC: 11496930. DOI: 10.1016/j.celrep.2024.114811.

References

Wen X, Pickens J, Mousa J, Leser G, Lamb R, Crowe Jr J . A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. PLoS One. 2016; 11(5):e0155917. PMC: 4880302. DOI: 10.1371/journal.pone.0155917. View

Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G . Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013; 501(7467):439-43. DOI: 10.1038/nature12442. View

Edwards K, Zhu Y, Griffin M, Weinberg G, Hall C, Szilagyi P . Burden of human metapneumovirus infection in young children. N Engl J Med. 2013; 368(7):633-43. PMC: 3662802. DOI: 10.1056/NEJMoa1204630. View

McLellan J, Chen M, Leung S, Graepel K, Du X, Yang Y . Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340(6136):1113-7. PMC: 4459498. DOI: 10.1126/science.1234914. View

Schmidt A, Therkelsen M, Stewart S, Kepler T, Liao H, Moody M . Viral receptor-binding site antibodies with diverse germline origins. Cell. 2015; 161(5):1026-1034. PMC: 4441819. DOI: 10.1016/j.cell.2015.04.028. View

Mas V, Rodriguez L, Olmedillas E, Cano O, Palomo C, Terron M . Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathog. 2016; 12(9):e1005859. PMC: 5017722. DOI: 10.1371/journal.ppat.1005859. View

Stewart-Jones G, Thomas P, Chen M, Druz A, Joyce M, Kong W . A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS One. 2015; 10(6):e0128779. PMC: 4476739. DOI: 10.1371/journal.pone.0128779. View

Swanson K, Settembre E, Shaw C, Dey A, Rappuoli R, Mandl C . Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A. 2011; 108(23):9619-24. PMC: 3111287. DOI: 10.1073/pnas.1106536108. View

Joyce M, Zhang B, Ou L, Chen M, Chuang G, Druz A . Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol. 2016; 23(9):811-820. PMC: 5016229. DOI: 10.1038/nsmb.3267. View

10.

Yin H, Wen X, Paterson R, Lamb R, Jardetzky T . Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature. 2006; 439(7072):38-44. PMC: 7095149. DOI: 10.1038/nature04322. View

11.

Storoni L, McCoy A, Read R . Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 3):432-8. DOI: 10.1107/S0907444903028956. View

12.

. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998; 102(3 Pt 1):531-7. View

13.

Smith S, Zhou Y, Olivarez N, Broadwater A, de Silva A, Crowe Jr J . Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol. 2011; 86(5):2665-75. PMC: 3302281. DOI: 10.1128/JVI.06335-11. View

14.

Zwart P, Afonine P, Grosse-Kunstleve R, Hung L, Ioerger T, McCoy A . Automated structure solution with the PHENIX suite. Methods Mol Biol. 2008; 426:419-35. DOI: 10.1007/978-1-60327-058-8_28. View

15.

Hall C, Simoes E, Anderson L . Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372:39-57. DOI: 10.1007/978-3-642-38919-1_2. View

16.

Wen X, Krause J, Leser G, Cox R, Lamb R, Williams J . Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nat Struct Mol Biol. 2012; 19(4):461-3. PMC: 3546531. DOI: 10.1038/nsmb.2250. View

17.

Adams P, Grosse-Kunstleve R, Hung L, Ioerger T, McCoy A, Moriarty N . PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002; 58(Pt 11):1948-54. DOI: 10.1107/s0907444902016657. View

18.

Zhou T, Lynch R, Chen L, Acharya P, Wu X, Doria-Rose N . Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell. 2015; 161(6):1280-92. PMC: 4683157. DOI: 10.1016/j.cell.2015.05.007. View

19.

Schuster J, Cox R, Hastings A, Boyd K, Wadia J, Chen Z . A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis. 2014; 211(2):216-25. PMC: 4342691. DOI: 10.1093/infdis/jiu307. View

20.

McLellan J, Yang Y, Graham B, Kwong P . Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85(15):7788-96. PMC: 3147929. DOI: 10.1128/JVI.00555-11. View